Innovations in radiotherapy planning of head and neck cancers: role of PET.
Modern radiotherapy techniques heavily rely on high-quality medical imaging. PET provides biologic information about the tumor, complementary to anatomic imaging. Integrated PET/CT has found its way into the practice of radiation oncology, and (18)F-FDG PET is being introduced for radiotherapy planning. The functional information possibly augments accurate delineation and treatment of the tumor and its extensions while reducing the dose to surrounding healthy tissues. In addition to (18)F-FDG, other PET tracers are available for imaging specific biologic tumor characteristics determining radiation resistance. For head and neck cancer, the potential gains of PET are increasingly being recognized. This review describes the current role of PET and perspectives on its future use for selection and delineation of radiotherapy target volumes and for biologic characterization of this tumor entity. Furthermore, the potential role of PET for early response monitoring, treatment modification, and patient selection is addressed in this review.
Troost
Esther G C
EG
Department of Radiation Oncology, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands. e.troost@rther.umcn.nl
Schinagl
Dominic A X
DA
Bussink
Johan
J
Boerman
Otto C
OC
van der Kogel
Albert J
AJ
Oyen
Wim J G
WJ
Kaanders
Johannes H A M
JH
D015687:Cell Hypoxia; D049109:Cell Proliferation; D019788:Fluorodeoxyglucose F18; D006258:Head and Neck Neoplasms / Q000098:blood supply / Q000000981:diagnostic imaging* / Q000473:pathology / Q000532:radiotherapy*; D006801:Humans; D009363:Neoplasm Proteins / Q000096:biosynthesis / Q000235:genetics; D010347:Patient Care Planning; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D012039:Regional Blood Flow; D014057:Tomography, X-Ray Computed
D009363:Neoplasm Proteins; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18